Senti Biosciences, Inc. (NASDAQ:SNTI) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) have received an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $9.00.

Several analysts have recently issued reports on SNTI shares. HC Wainwright started coverage on shares of Senti Biosciences in a research note on Tuesday, October 14th. They set a “buy” rating and a $12.00 price objective for the company. Leerink Partnrs raised Senti Biosciences to a “strong-buy” rating in a research report on Friday, November 21st. Chardan Capital upped their price target on Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research note on Wednesday, October 8th. Finally, Leerink Partners assumed coverage on Senti Biosciences in a report on Friday, November 21st. They set an “outperform” rating and a $6.00 target price for the company.

Senti Biosciences Price Performance

NASDAQ SNTI opened at $1.20 on Tuesday. The company has a market cap of $31.55 million, a P/E ratio of -0.36 and a beta of 2.08. Senti Biosciences has a 12 month low of $1.15 and a 12 month high of $5.10. The company has a 50-day moving average of $1.88 and a 200-day moving average of $1.88.

Senti Biosciences (NASDAQ:SNTI) last released its earnings results on Thursday, November 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.10). As a group, equities research analysts anticipate that Senti Biosciences will post -14.54 EPS for the current year.

Hedge Funds Weigh In On Senti Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Armistice Capital LLC acquired a new stake in Senti Biosciences in the 2nd quarter valued at $1,883,000. Nantahala Capital Management LLC acquired a new stake in shares of Senti Biosciences in the first quarter valued at about $2,984,000. Heights Capital Management Inc. purchased a new stake in shares of Senti Biosciences during the 1st quarter valued at about $2,520,000. Geode Capital Management LLC lifted its position in Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in Senti Biosciences in the 3rd quarter worth approximately $117,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.